Welcome to our dedicated page for CME GROUP SEC filings (Ticker: CME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CME Group Inc. SEC filings document the financial results, governance matters and market-infrastructure disclosures of a derivatives exchange and clearing operator. Form 8-K reports cover quarterly and annual results, GAAP and non-GAAP measures, pricing disclosures, material agreements and other events tied to the company’s trading, clearing, benchmark and market data activities.
The filings also describe clearing-house liquidity arrangements, including amendments to a multi-currency secured credit facility used for temporary liquidity needs related to clearing obligations and collateral mechanics. Proxy materials cover executive compensation, pay-versus-performance data, shareholder voting matters and governance. Other event reports have addressed officer transition disclosures and legal matters involving CME Group and the Board of Trade of the City of Chicago.
CME GROUP INC. (CME) reported that Chief Information Officer Sunil Cutinho received a grant of 2,864 shares of Class A common stock on September 15, 2026 as restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service. On September 15 and 16, he surrendered a total of 1,413 shares to CME Group to satisfy tax withholding obligations related to the vesting of previously granted restricted stock.
CME GROUP INC. (CME) received a notice that officer Jonathan Marcus plans to sell common stock under Rule 144. The filing lists a proposed sale of 388 shares of common stock of CME Group through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ market.
The aggregate value associated with the shares indicated is $106,102.48, with the securities described as restricted stock to be sold for the account of Jonathan Marcus.
CME GROUP INC. (CME) reported that John Clifford Marchese, who serves as Sr MD, General Counsel, filed an initial statement of beneficial ownership of securities. The filing lists 3,055 shares of Common Stock Class A held with direct ownership, with no specific purchase or sale transaction reported.
CME GROUP INC. (CME) director Elizabeth A. Cook reported the sale of 500 shares of Class A common stock on September 14, 2026 at $280.11 per share through an entity described as a trust. Following this transaction, the trust holds 17,916 shares, and a separate joint account is reported holding 20 shares, both as indirect ownership. No Rule 10b5-1 trading plan is reported for these transactions.
CME GROUP INC. (CME) received a notice of proposed sale of restricted shares under Rule 144. The Elizabeth Anne Cook Trust plans to sell 500 shares of common stock through Morgan Stanley Smith Barney LLC, with an indicated aggregate sale value of $140,052.50 on or about September 14, 2026.
The trust’s shares are noted as restricted stock acquired from the issuer on June 25, 2025, and are to be sold on the NASDAQ market.
CME GROUP INC. (CME) disclosed that Chairman and CEO Terrence A. Duffy sold a total of 15,000 shares of Class A common stock on September 10, 2026 in open-market or private transactions. The filing states these sales were not made under a Rule 10b5-1 trading plan and reports no post-transaction share balance.
CME GROUP INC. (CME) has a notice of proposed sale of common stock filed on behalf of officer Terrence Duffy under Rule 144. The filing covers up to 15,000 shares of CME common stock to be sold through Merrill, with an aggregate market value of $4,125,000 and Nasdaq listed as the trading market.
The shares relate to executive compensation grants to Terrence Duffy dated December 31, 2024 for 5,169 shares and December 31, 2025 for 12,970 shares.
CME Group Inc. (CME) announced a set of senior leadership changes in its finance and legal divisions. Jack Tobin, age 63, will be appointed Managing Director, Deputy Chief Financial Officer effective November 2, 2026, and is expected to become Chief Financial Officer in March 2027 when current President & CFO Lynne Fitzpatrick becomes CEO as previously disclosed. As CFO, Tobin will join the company’s management team.
Matthew Render, age 47, will succeed Tobin as Managing Director, Chief Accounting Officer effective November 2, 2026, after joining CME Group as Deputy Chief Accounting Officer in August 2026. The company states Render’s appointment is not pursuant to any arrangement with another person, there are no family relationships with directors or executives, and he has no material interests in related-party transactions requiring disclosure under Item 404(a) of Regulation S‑K. In the legal division, John Marchese will be promoted to General Counsel and join the management team later in September 2026, succeeding Jonathan Marcus, who is stepping down after serving as General Counsel since 2022.
CME Group Inc. reports that on August 11, 2026 it communicated pricing changes to its clients through Special Executive Report No. 9799, with the notice made available on the company’s website. The disclosure is presented under Regulation FD to ensure broad, non-selective dissemination of this information.
The report also identifies Exhibit 104 as the cover page formatted in Inline XBRL, supporting electronic data use and compliance with SEC technical requirements.
CME Group Inc. reported Q2 2026 total revenues of $1,706.2 million, slightly above Q2 2025. Net income was $1,041.8 million with diluted EPS of $2.88, compared with $1,025.1 million and $2.81 a year earlier.
For the six months ended June 30, 2026, revenues reached $3,586.3 million and net income $2,196.1 million, with diluted EPS of $6.06. Clearing and transaction fees dipped in Q2 but rose year to date, while market data and information services grew strongly. Total assets were $194,676.6 million, long-term debt $3,424.2 million, and operating cash flow $2,207.0 million. The company returned capital through $3,171.8 million of common dividends and repurchased 4,384,776 Class A shares for $1.2 billion, leaving $1.5 billion under its existing buyback program.